
ASCO 25: AZ pitches upfront oral SERD use in breast cancer
AstraZeneca wants to make its oral selective oestrogen receptor degrader (SERD) drug camizestrant a go-to frontline therapy for HR-positive breast cancer, and made its case at ASCO with data from the SERENA-6 trial. The reveal of results first signposted …